Diagnosed common Parkinson’s disease cases projected to reach 3.15 million in seven major markets by 2033 – Health News

Common cases diagnosed Parkinson’s disease (PD) According to leading data and analytics company GlobalData, sales in seven major markets (7MM) are expected to grow from 2.64 million in 2023 to 3.15 million in 2033, with an annual growth rate (AGR) of 1.94 percent.

The seven major markets include the US, France, Germany, Italy, Spain, UK and Japan.

GlobalData’s latest report, “Parkinson’s Disease Epidemiology Analysis and 2033 Forecast,” estimates that in 2033, the United States will have the most diagnosed cases of prevalent Parkinson’s at 1.24 million in 7MM, while Italy will have approximately 0.16 million cases. It is predicted to happen. , will have the lowest number.

Best Senior Citizen Fixed Deposits for November – Check latest interest rates

Lancet study finds a quarter of global diabetes cases in India; Doctor encourages lifestyle changes to curb rise

To challenge shortening life expectancy, companies need to stay ahead of the curve and innovate: Deepak Parekh

Parkinson’s disease clinical trial in seven major markets focuses on disease-modifying agents

“In 2023, more than 90% of prevalent Parkinson’s cases diagnosed in 7MM were adults aged 60 and over, while adults aged 18-39 accounted for less than 1%. This age distribution indicates a higher prevalence of Parkinson’s disease in older populations.” Consistent with the findings, there is a slight preponderance of gender-specific diagnosed cases in favor of men, with differences between genders and markets mostly attributable to underlying demographic differences within each gender. SundayGlobalData Senior Epidemiologist Rahul N Ravi, MPH, said:

PD is an incurable neurodegenerative disease that is clinically classified as a movement disorder with prominent motor symptoms such as tremor, rigidity, and bradykinesia. It is the second most common chronic progressive neurodegenerative disease in the elderly after Alzheimer’s disease. While current treatments provide symptomatic relief, there is no treatment that will stop or slow the progression of the disease.

Ravi concludes: “PD is among the most common chronic, progressive neurodegenerative diseases affecting the elderly population. Because PD predominantly affects older adults, countries with growing aging populations must develop strategies to meet the healthcare needs of individuals with PD. Over the next decade, 7MM’ “It is expected to be very important for Parkinson’s treatment due to their aging populations.”